AbbVie is a drug manufacturers - general business based in the US. AbbVie shares (ABBV) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $170.67 – a decrease of 0.52% over the previous week. AbbVie employs 50,000 staff and has a trailing 12-month revenue of around $55.5 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $170.67 |
|---|---|
| 52-week range | $149.56 - $205.38 |
| 50-day moving average | $176.85 |
| 200-day moving average | $178.62 |
| Wall St. target price | $199.97 |
| PE ratio | 58.75 |
| Dividend yield | $6.2 (3.88%) |
| Earnings per share (TTM) | $2.88 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $169.2 from 2025-01-22
| 1 week (2025-01-17) | -1.38% |
|---|---|
| 1 month (2024-12-24) | -6.00% |
| 3 months (2024-10-24) | -10.78% |
| 6 months (2024-07-24) | -3.98% |
| 1 year (2024-01-24) | 3.03% |
|---|---|
| 2 years (2023-01-24) | 23.55% |
| 3 years (2022-01-24) | 43.32% |
| 5 years (2020-01-24) | 149.99% |
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, AbbVie shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3997. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $25.6 billion.
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $55.5 billion |
|---|---|
| Operating margin TTM | 28.93% |
| Gross profit TTM | $39.1 billion |
| Return on assets TTM | 7.72% |
| Return on equity TTM | 56.41% |
| Profit margin | 9.22% |
| Book value | $3.41 |
| Market Capitalization | $299 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 12/31/2018) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
AbbVie Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 34.86 |
|---|---|
| Total ESG percentile | 65.78 |
| Environmental score | 4.96 |
| Environmental score percentile | 7 |
| Social score | 22.65 |
| Social score percentile | 7 |
| Governance score | 16.25 |
| Governance score percentile | 7 |
| Level of controversy | 3 |
Dividend payout ratio: 58.51% of net profits
Recently AbbVie has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $6.2 per share.
AbbVie's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AbbVie's most recent dividend payout was on 13 February 2025. The latest dividend was paid out to all shareholders who bought their shares by 14 January 2025 (the "ex-dividend date").
Over the last 12 months, AbbVie's shares have ranged in value from as little as $149.557 up to $205.3832. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.613. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Find out more about this component of your brokerage account and how you can use this cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.